Anika Therapeutics (ANIK) Received European CE Mark for Aesthetic 'ELEVESS Light'
More News related to ANIK
- Anika Therapeutics Inc. (ANIK) Posts Q4 non-GAAP EPS of $0.17, Tops Y/Y
- Anika Therapeutics Reports 18% Revenue Growth in Fourth-Quarter 2009
- Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2009 Financial Results Conference Call
- Anika Therapeutics to Webcast Presentation at Canaccord Adams Musculoskeletal Conference
- Notable Mergers and Acquisitions of the Day 12/31: ANIK, AMT, WTR, TRN/QUIX
More News related to Corporate News
- Apple (AAPL) Accepting iPad Applications for Review Today; Telling Developers to Submit App by March 27 for April 3 Launch
- Alanco Technologies (ALAN) Receives Non-Compliance Notification From NASDAQ
- Fed ends exemptions to banks aimed at adding mortgage liquidity
- Citi (C) Reverses Decision to Shrink Home-Lending Business; To Boost Purchases of Mortgages Sold by Other Banks -Bloomberg
- IBM Announces Addition of 200 Partners to LotusLive Cloud Services
Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that it has received European CE Mark approval for "ELEVESS Light," the Company's latest aesthetic product used for the treatment of fine lines and facial wrinkles. ELEVESS Light will be distributed in the European market by the Company's current aesthetic dermatology distributors.
"This approval expands our aesthetic dermatology product family and paves the way for an early 2010 launch of 'ELEVESS Light' in the European Union and other geographies that provide approvals based on the CE mark," said Charles H. Sherwood, Ph.D., Anika's President and Chief Executive Officer. "Domestically, we are in discussions with the FDA about the pathway for approval for this new fine-line product."
Related Categories
Corporate NewsStocks Mentioned
+0.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
